Handelsbanken Fonder Ab Day One Biopharmaceuticals, Inc. Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
A detailed history of Handelsbanken Fonder Ab transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 27,000 shares of DAWN stock, worth $367,740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,000
Previous 23,100
16.88%
Holding current value
$367,740
Previous $318,000
18.24%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
84MCall Options Held
144KPut Options Held
218K-
Ra Capital Management, L.P. Boston, MA7.87MShares$107 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$87.6 Million11.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$80.2 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$66.4 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$61.7 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...